Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours

Veterinary and Comparative Oncology

Volumn 7, Issue 2, 2009, Pages 106-114

  Shiomitsu, K ^a,c   Johnson, C L ^a   Malarkey, D E ^b   Pruitt, A F ^a   Thrall, D E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Canine; EGFR; Nasal tumour; Radiosensitivity; VEGF

Indexed keywords

CANIS FAMILIARIS;

EID: 65749111222     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00178.x     Document Type: Article

References (45)

1. Yarden Y and Sliwkowski MX. Untangling the ErbB signaling network. Nature Reviews. Molecular Cell Biology 2001; 2: 127-137.
2. Thariat J, Milas L and Ang KK. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. International Journal of Radiation Oncology, Biology, Physics 2007; 69: 974-984.
3. Liang K, Ang KK, Milas L, Hunter N and Fan Z. The epidermal growth factor receptor mediates radioresistance. International Journal of Radiation Oncology, Biology, Physics 2003; 57: 246-254.
4. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research 2002; 62: 7350-7356.
5. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F and Milano G. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouraci. British Journal of Cancer 1999; 79: 1864-1869.
6. Huang SM and Harari PM. Modulation of radiation response after epidermal growth factor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clinical Cancer Research 2000; 6: 2166-2174.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006; 354: 567-578.
8. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, Lobuglio AF, Peters GE, Carroll WR and Waksal HW. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. Journal of Clinical Oncology 2000; 18: 47S-53S.
9. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA and Cullinane C. EGFR blockade with ZD ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 dquamous cell carcinoma. Epidermal growth factor receptor. International Journal of Radiation Oncology, Biology, Physics 2003; 55: 713-723.
10. Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R and Claesson-Welsh L. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Research 2004; 64: 9012-9017.
11. Cébe-Suarez S, Zehnder-Fjällman A and Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cellular Molecular Life Sciences 2006; 63: 601-615.
12. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of Clinical Oncology 2002; 20: 4368-4380.
13. Carmeliet P and Jain RK. Angiogenesis in cancer and other disease. Nature 2000; 407: 249-257.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004; 350: 2335-2342.
15. Li J, Huang S, Armstrong EA, Fowler JF and Harari PM. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. International Journal of Radiation Oncology, Biology, Physics 2005; 62: 1477-1485.
16. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematololgy 2007; 62: 179-213.
17. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE and Hicklin DJ. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clinical Cancer Research 2006; 12: 2197-2207.
18. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK and Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology 2005; 23: 2544-2555.
19. Looper JS, Malarkey DE, Ruslander D, Proulx D and Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Veterinary and Comparative Oncology 2006; 4: 33-40.
20. Platt SR, Scase TJ, Adams V, Wieczorek L, Miller J, Adamo F and Long S. Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival. Journal of Veterinary Internal Medicine 2006; 20: 638-663.
21. Taylor KH, Smith AN, Higginbotham M, Schwartz DD, Carpenter DM and Whitley EM. Expression of vascular endothelial growth factor in canine oral malignant melanoma. Veterinary and Comparative Oncology 2007; 5: 208-218.
22. Chua DT, Nicholls JM, Sham JS and Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2004; 59: 11-20.
23. MacEwen GE, Withrow SJ and Patnaik AK. Nasal tumors in the dog: retrospective evaluation of diagnosis, prognosis, and treatment. Journal of the American Veterinary Medical Association 1977; 170: 45-48.
24. Noris AM. Intranasal neoplasms in the dog. Journal of the American Hospital Association 1979; 15: 231-236.
25. Adams WM, Bjorling DE, McAnulty JF, Green EM, Forrest LJ and Vail DM. Outcome of accelerated radiotherapy alone or accelerated radiotherapy followed by exenteration of the nasal cavity in dogs with intranasal neoplasia: 53 cases (1990-2002). Journal of the American Veterinary Medical Association 2005; 227: 936-941.
26. Lana SE, Dernell WS, LaRue SM, Lafferty MJ, Douple EB, Brekke JH and Withrow SJ. Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Veterinary Radiology & Ultrasound 1997; 38: 474-478.
27. Adams WM, Miller PE, Vail DM, Forrest LJ and MacEwen GE. An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors. Veterinary Radiology & Ultrasound 1998; 39: 475-481.
28. Wilsson DW and Dungworth DL. Tumors of the respiratory tract. In: Tumors in Domestic Animals, 4th. edn., DJ Meuten, ed., Ames, A Blackwell Publishing Company, 2002: 365-400.
29. Dungworth DL, Hauser B, Hahn FF, Wilson DW, Haenichen T and Harkema JR. Histological classification of the tumors of the respiratory system of domestic animals. World Health Organization International Histological Classification of Tumors of Domestic Animals 1999; 6: 16-21.
30. Park K, Han S, Shin E, Kim HJ and Kim JY. EGFR gene and protein expression in breast cancers. European Journal of Surgical Oncology 2007; 33: 956-960.
31. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G and Buerger H. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcoma. Journal of Clinical Pathology 2006; 59: 181-193.
32. Pratt MA, White D, Kushwaha N, Tibbo E and Niu MY. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis 2007; 12: 657-669.
33. Kiupel M, Webster JD, Kaneene JB, Miller R and Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary Pathology 2004; 41: 371-377.
34. Tuettenberg J, Friedel C and Vajkoczy P. Angiogenesis in malignant glioma - a target for antitumor therapy? Critical Reviews in Oncology Hematology 2006; 59: 181-193.
35. Ribatti D, Conconi MT and Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Phamacological Reviews 2007; 59: 185-205.
36. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R and Rodemann HP. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. The Journal of Biological Chemistry 2005; 280: 31182-31189.
37. Hall EJ. Oxygen effect and reoxygenation. In: Radiobiology for the Radiologist, 6th. edn., H Eric, ed., Philadelphia, Lippincott Williams & Wilkins, 2006: 85-105.
38. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
39. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL and Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinase. Cancer Cell 2004; 6: 553-563.
40. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, Morelli MP, Cascone T and Tortora G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for multi-target anticancer therapy. Annals of Oncology 2006; 17: Vii109-vii114.
41. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S and Jass JR. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. British Journal of Cancer 2008; 98: 450-456.
42. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS and Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. Journal of Histochemistry and Cytochemistry 2004; 52: 893-901.
43. Chung CH, Ely 1 K, Mcgavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levyt S, Yarbrough WG, Slebos RJ and Hirsch FR. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Journal of Clinical Oncology 2006; 24: 4170-4176.
44. Teman S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ and Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Journal of Clinical Oncology 2007; 25: 2164-2170.
45. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T and Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology 2005; 23: 6829-6837.